Sellas Life Sciences Group Inc. surged after the drug developer reported positive late-stage trial results for an experimental cancer vaccine to treat an aggressive form of blood cancer.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.
